The results showed that the intratumoral infiltration of CD8+ T cells was significantly increased in the combination therapy group containing anti-PD-1; in addition, the combination therapy significantly down-regulated the levels of PD-L1 and CD206 in the tumor (Figure 6). Here, MRC1 is linked to neoplasm.